Despite significant evidence of pro‐tumorigenic role of TECs secreted IL‐33 in CRC by inhibiting anti‐tumor immunity, remodelling tumor stroma, and enhancing angiogenesis [147], few studies have reported the anti‐tumorigenic effect of IL‐33 in CRC as well [148, 149, 150]. This evidence concerns the gene IL33 and colorectal carcinoma.